Bristol Defends Biomarker Strategy At ASCO, Expects Broad Label In Lung
Executive Summary
In the CheckMate 057 non-squamous NSCLC study, patients with low expression of PD-L1 taking Opdivo did not have better overall survival or response rates compared to docetaxel, but the duration of response was long and the PD-1 inhibitor has a far better safety profile.